Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 313 to 317 of 317 entries
Sorted by: Best Match Show Resources per page
Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.

Ophthalmology and therapy

Cockerham KP, Padnick-Silver L, Stuertz N, Francis-Sedlak M, Holt RJ.
PMID: 34478126
Ophthalmol Ther. 2021 Dec;10(4):975-987. doi: 10.1007/s40123-021-00385-8. Epub 2021 Sep 03.

INTRODUCTION: Thyroid eye disease (TED) is an autoimmune condition producing ocular pain, dysmotility, and ocular structure and function changes. As disease activity changes, redness, swelling, and pain can improve, but eye comfort, appearance, and motility alterations often persist. There...

Cite
Cockerham KP, Padnick-Silver L, Stuertz N, et al. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States. Ophthalmol Ther. 2021;10(4):975-987doi: 10.1007/s40123-021-00385-8.
Cockerham, K. P., Padnick-Silver, L., Stuertz, N., Francis-Sedlak, M., & Holt, R. J. (2021). Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States. Ophthalmology and therapy, 10(4), 975-987. https://doi.org/10.1007/s40123-021-00385-8
Cockerham, Kimberly P, et al. "Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States." Ophthalmology and therapy vol. 10,4 (2021): 975-987. doi: https://doi.org/10.1007/s40123-021-00385-8
Cockerham KP, Padnick-Silver L, Stuertz N, Francis-Sedlak M, Holt RJ. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States. Ophthalmol Ther. 2021 Dec;10(4):975-987. doi: 10.1007/s40123-021-00385-8. Epub 2021 Sep 03. PMID: 34478126; PMCID: PMC8589903.
Copy Download .nbib Format: NLM
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.

The oncologist

Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U, Harshman LC, Vaishampayan UN, Necchi A, Srinivas S, Pal SK, Niegisch G, Dorff TB, Galsky MD, Yu EY.
PMID: 34355457
Oncologist. 2021 Dec;26(12):1026-1034. doi: 10.1002/onco.13925. Epub 2021 Aug 17.

BACKGROUND: Fit patients with metastatic urothelial carcinoma (mUC) receive first-line platinum-based combination chemotherapy (fPBC) as standard of care and may receive additional later-line chemotherapy after progression. Our study compares outcomes with subsequent platinum-based chemotherapy (sPBC) versus subsequent non-platinum-based chemotherapy...

Cite
Wong RL, Ferris LA, Do OA, et al. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist. 2021;26(12):1026-1034doi: 10.1002/onco.13925.
Wong, R. L., Ferris, L. A., Do, O. A., Holt, S. K., Ramos, J. D., Crabb, S. J., Sternberg, C. N., Bellmunt, J., Ladoire, S., De Giorgi, U., Harshman, L. C., Vaishampayan, U. N., Necchi, A., Srinivas, S., Pal, S. K., Niegisch, G., Dorff, T. B., Galsky, M. D., & Yu, E. Y. (2021). Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. The oncologist, 26(12), 1026-1034. https://doi.org/10.1002/onco.13925
Wong, Risa L, et al. "Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease." The oncologist vol. 26,12 (2021): 1026-1034. doi: https://doi.org/10.1002/onco.13925
Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U, Harshman LC, Vaishampayan UN, Necchi A, Srinivas S, Pal SK, Niegisch G, Dorff TB, Galsky MD, Yu EY. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist. 2021 Dec;26(12):1026-1034. doi: 10.1002/onco.13925. Epub 2021 Aug 17. PMID: 34355457.
Copy Download .nbib Format: NLM
Automated Breast Volume Assessment Derived From Digital Breast Tomosynthesis Images Compared to Mastectomy Specimen Weight and Its Applications in Cosmetic Optimisation.

Cureus

Munir A, Huws AM, Khawaja S, Khan S, Holt S, Sharaiha Y.
PMID: 34926087
Cureus. 2021 Nov 16;13(11):e19642. doi: 10.7759/cureus.19642. eCollection 2021 Nov.

BACKGROUND: Estimating the size and volume of the breast preoperatively is an important step in surgical planning for many breast procedures such as immediate implant-based breast reconstructions and reduction mammoplasties. Breast volume estimation helps in appropriate implant selection preoperatively.OBJECTIVES:...

Cite
Munir A, Huws AM, Khawaja S, et al. Automated Breast Volume Assessment Derived From Digital Breast Tomosynthesis Images Compared to Mastectomy Specimen Weight and Its Applications in Cosmetic Optimisation. Cureus. 2021;13(11):e19642doi: 10.7759/cureus.19642.
Munir, A., Huws, A. M., Khawaja, S., Khan, S., Holt, S., & Sharaiha, Y. (2021). Automated Breast Volume Assessment Derived From Digital Breast Tomosynthesis Images Compared to Mastectomy Specimen Weight and Its Applications in Cosmetic Optimisation. Cureus, 13(11), e19642. https://doi.org/10.7759/cureus.19642
Munir, Asma, et al. "Automated Breast Volume Assessment Derived From Digital Breast Tomosynthesis Images Compared to Mastectomy Specimen Weight and Its Applications in Cosmetic Optimisation." Cureus vol. 13,11 (2021): e19642. doi: https://doi.org/10.7759/cureus.19642
Munir A, Huws AM, Khawaja S, Khan S, Holt S, Sharaiha Y. Automated Breast Volume Assessment Derived From Digital Breast Tomosynthesis Images Compared to Mastectomy Specimen Weight and Its Applications in Cosmetic Optimisation. Cureus. 2021 Nov 16;13(11):e19642. doi: 10.7759/cureus.19642. eCollection 2021 Nov. PMID: 34926087; PMCID: PMC8673690.
Copy Download .nbib Format: NLM
Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study.

Rheumatology and therapy

Francis-Sedlak M, LaMoreaux B, Padnick-Silver L, Holt RJ, Bello AE.
PMID: 33284422
Rheumatol Ther. 2021 Mar;8(1):183-197. doi: 10.1007/s40744-020-00260-1. Epub 2020 Dec 07.

INTRODUCTION: Gout is a common, progressive, systemic inflammatory arthritis caused by hyperuricemia. Current guidelines recommend that serum uric acid (sUA) levels be maintained below 6.0 mg/dl to minimize acute gout attacks, tophi development, and long-term joint and organ damage....

Cite
Francis-Sedlak M, LaMoreaux B, Padnick-Silver L, et al. Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study. Rheumatol Ther. 2020;8(1):183-197doi: 10.1007/s40744-020-00260-1.
Francis-Sedlak, M., LaMoreaux, B., Padnick-Silver, L., Holt, R. J., & Bello, A. E. (2021). Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study. Rheumatology and therapy, 8(1), 183-197. https://doi.org/10.1007/s40744-020-00260-1
Francis-Sedlak, Megan, et al. "Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study." Rheumatology and therapy vol. 8,1 (2021): 183-197. doi: https://doi.org/10.1007/s40744-020-00260-1
Francis-Sedlak M, LaMoreaux B, Padnick-Silver L, Holt RJ, Bello AE. Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study. Rheumatol Ther. 2021 Mar;8(1):183-197. doi: 10.1007/s40744-020-00260-1. Epub 2020 Dec 07. PMID: 33284422; PMCID: PMC7991061.
Copy Download .nbib Format: NLM
Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States.

Ophthalmology and therapy

Wang Y, Sharma A, Padnick-Silver L, Francis-Sedlak M, Holt RJ, Foley C, Massry G, Douglas RS.
PMID: 33196932
Ophthalmol Ther. 2021 Mar;10(1):75-87. doi: 10.1007/s40123-020-00318-x. Epub 2020 Nov 16.

INTRODUCTION: Thyroid eye disease (TED) is an autoimmune disease that causes retro-orbital inflammation and subsequent proptosis, corneal exposure, strabismus, and variable vision changes. European studies have shown that TED can severely impact quality of life (QOL), but little is...

Cite
Wang Y, Sharma A, Padnick-Silver L, et al. Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States. Ophthalmol Ther. 2020;10(1):75-87doi: 10.1007/s40123-020-00318-x.
Wang, Y., Sharma, A., Padnick-Silver, L., Francis-Sedlak, M., Holt, R. J., Foley, C., Massry, G., & Douglas, R. S. (2021). Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States. Ophthalmology and therapy, 10(1), 75-87. https://doi.org/10.1007/s40123-020-00318-x
Wang, Yao, et al. "Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States." Ophthalmology and therapy vol. 10,1 (2021): 75-87. doi: https://doi.org/10.1007/s40123-020-00318-x
Wang Y, Sharma A, Padnick-Silver L, Francis-Sedlak M, Holt RJ, Foley C, Massry G, Douglas RS. Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States. Ophthalmol Ther. 2021 Mar;10(1):75-87. doi: 10.1007/s40123-020-00318-x. Epub 2020 Nov 16. PMID: 33196932; PMCID: PMC7886952.
Copy Download .nbib Format: NLM
Showing 313 to 317 of 317 entries